Key result
Higher plasma Urotensin II linked to ~6-fold higher odds of metabolic syndrome in T2D.
Why the study?
Are plasma Urotensin II levels associated with the presence of metabolic syndrome in patients with type 2 diabetes mellitus?
Cross-Sectional (n=360)
Are plasma Urotensin II levels associated with the presence of metabolic syndrome in patients with type 2 diabetes mellitus?
Odds Ratio: 6.41 (95% CI 1.21–16.04)
p-value: p=0.02
Elevated plasma Urotensin II levels are significantly associated with the presence of metabolic syndrome in patients with type 2 diabetes, suggesting a potential role in disease progression.
Hypothesis-generating for Urotensin II in T2D metabolic syndrome; prospective validation needed before clinical adoption.
Urotensin II (UII) exerts multiple effects on the cardiovascular system, acts as a diabetogenic agent, and may also contribute to the development of the metabolic syndrome (MetS). The aim of this study was to determine circulating UII in patients with type 2 diabetes mellitus (T2DM) and its relationship with MetS. A total of 360 consecutive patients with T2DM were included. MetS presence/absence (MetS [+]/[-]) was defined according to American Heart Association/National Heart, Lung and Blood Institute criteria. Plasma concentrations of UII were determined by radioimmunoassay. UII levels were significantly higher in MetS (+) than in MetS (-) T2DM patients (0.97 pg/mL [0.93-1.01], n=294 vs 0.82 pg/mL [0.75-0.88] pg/mL, n=66, respectively; P<.001). Multiple logistic regression analysis showed that UII was significantly associated with MetS (+) (odds ratio, 6.41 [95% confidence interval, 1.21-16.04]; P=.02). UII plasma concentrations are significantly higher in T2DM patients presenting with MetS. Therefore, circulating UII may participate in the worsening course of some T2DM patients and may provide novel therapeutic perspectives.
No takes yet. Share an insight, caveat, or question.
Gruson et al. (2010) conducted a cross-sectional in Type 2 diabetes mellitus (T2DM) (n=360). Plasma Urotensin II (UII) was evaluated on Presence of metabolic syndrome (MetS) (OR 6.41, 95% CI 1.21-16.04, p=0.02). Plasma Urotensin II concentrations were significantly associated with the presence of metabolic syndrome in patients with type 2 diabetes (OR 6.41; 95% CI 1.21-16.04; P=0.02).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: